EA201891007A1 - Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца - Google Patents

Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца

Info

Publication number
EA201891007A1
EA201891007A1 EA201891007A EA201891007A EA201891007A1 EA 201891007 A1 EA201891007 A1 EA 201891007A1 EA 201891007 A EA201891007 A EA 201891007A EA 201891007 A EA201891007 A EA 201891007A EA 201891007 A1 EA201891007 A1 EA 201891007A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
fpr2
lipoxin
alx
formilpeptid
Prior art date
Application number
EA201891007A
Other languages
English (en)
Russian (ru)
Inventor
Ясек Островский
Рикардо Гарсиа
Николас Р. Вуртц
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201891007A1 publication Critical patent/EA201891007A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201891007A 2015-11-24 2016-11-21 Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца EA201891007A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259498P 2015-11-24 2015-11-24
PCT/US2016/063036 WO2017091496A1 (en) 2015-11-24 2016-11-21 Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease

Publications (1)

Publication Number Publication Date
EA201891007A1 true EA201891007A1 (ru) 2018-11-30

Family

ID=57544530

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891007A EA201891007A1 (ru) 2015-11-24 2016-11-21 Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца

Country Status (13)

Country Link
US (1) US20180325869A1 (OSRAM)
EP (1) EP3380091A1 (OSRAM)
JP (1) JP2018538367A (OSRAM)
KR (1) KR20180081528A (OSRAM)
CN (1) CN108348479A (OSRAM)
AU (1) AU2016359463A1 (OSRAM)
BR (1) BR112018010155A8 (OSRAM)
CA (1) CA3006291A1 (OSRAM)
EA (1) EA201891007A1 (OSRAM)
IL (1) IL259468A (OSRAM)
MX (1) MX2018005756A (OSRAM)
SG (1) SG11201803816RA (OSRAM)
WO (1) WO2017091496A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102772801B1 (ko) 2015-12-10 2025-02-24 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
CN110997661B (zh) 2017-06-09 2023-03-31 百时美施贵宝公司 环丙基脲甲酰肽2受体和甲酰肽1受体激动剂
US11186544B2 (en) 2017-06-09 2021-11-30 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102615095B1 (ko) * 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
KR102615099B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
MY204384A (en) 2018-03-05 2024-08-27 Bristol Myers Squibb Co Phenylpyrrolidinone formyl peptide 2 receptor agonists
US12281108B2 (en) 2018-11-26 2025-04-22 Bristol-Myers Squibb Company Pyrrolidinone derivatives as formyl peptide 2 receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2225231B1 (en) * 2007-12-18 2011-08-17 Actelion Pharmaceuticals Ltd. Aminotriazole derivatives as alx agonists
WO2012066488A2 (en) * 2010-11-17 2012-05-24 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
CN104284887B (zh) * 2012-05-16 2016-06-22 埃科特莱茵药品有限公司 作为alx受体激动剂的经1-(对-甲苯基)环丙基取代的桥联螺[2.4]庚烷衍生物
KR102772801B1 (ko) * 2015-12-10 2025-02-24 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
MY204384A (en) * 2018-03-05 2024-08-27 Bristol Myers Squibb Co Phenylpyrrolidinone formyl peptide 2 receptor agonists

Also Published As

Publication number Publication date
KR20180081528A (ko) 2018-07-16
BR112018010155A8 (pt) 2019-02-26
CN108348479A (zh) 2018-07-31
IL259468A (en) 2018-07-31
JP2018538367A (ja) 2018-12-27
WO2017091496A1 (en) 2017-06-01
SG11201803816RA (en) 2018-06-28
BR112018010155A2 (pt) 2018-11-21
MX2018005756A (es) 2018-08-01
AU2016359463A1 (en) 2018-07-12
CA3006291A1 (en) 2017-06-01
US20180325869A1 (en) 2018-11-15
EP3380091A1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
EP4272757A3 (en) Modified nk-92 cells for treating cancer
CL2017002242A1 (es) Método para tratar un tumor cerebral
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX377438B (es) Administracion de tasimelteon en condiciones de ayuno.
PH12017500392A1 (en) Medical treatments based on anamorelin
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2016016491A (es) Derivados de o-alquil-bencilidenguanidina y uso terapeutico para el tratamiento de trastornos asociados con acumulacion de proteinas mal plegadas.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
EA201790220A1 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
EA201491048A1 (ru) Соединения двухцепочечных рнк к casp2 и их применение
UA128597U (uk) Спосіб лікування цереброваскулярних порушень головного мозку
EA202090336A1 (ru) Соединения, их соли и способы лечения заболеваний
UA98863U (en) Method for treating endometrial hyperplasia of patients of reproductive age
UA112489C2 (uk) Спосіб лікування вугрової хвороби шкіри обличчя та спини за індріксоном
RU2014116784A (ru) Способ лечения заболеваний пародонта
UA108454C2 (uk) Спосіб лікування метастазів головного мозку
UA96488U (uk) Спосіб лікування порушень гемоваскулярного гемостазу у хворих на ішемічну хворобу серця